MetLife Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

MetLife Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$196K	Buy	15,542 +1,134	+8%	+$15.2K	﹤0.01%	2240
2025 Q4	$227K	Buy	14,408 +7,849	+120%	+$99.7K	﹤0.01%	2207
2025 Q3	$78.5K	Sell	6,559 -6,456	-50%	-$51.6K	﹤0.01%	2737
2025 Q2	$98.4K	Sell	13,015 -64	-0.5%	-$385	﹤0.01%	2546
2025 Q1	$72.2K	Buy	+13,079	New	+$80.8K	﹤0.01%	2637
2024 Q4	–	Sell	-11,454	Closed	-$119K	–	2826
2024 Q3	$119K	Hold	11,454	–	–	﹤0.01%	2561
2024 Q2	$149K	Buy	11,454 +1,114	+11%	+$15K	﹤0.01%	2416
2024 Q1	$181K	Hold	10,340	–	–	﹤0.01%	2252
2023 Q4	$97.3K	Hold	10,340	–	–	﹤0.01%	2619
2023 Q3	$115K	Hold	10,340	–	–	﹤0.01%	2506
2023 Q2	$221K	Hold	10,340	–	–	﹤0.01%	2209
2023 Q1	$418K	Hold	10,340	–	–	﹤0.01%	1753
2022 Q4	$481K	Hold	10,340	–	–	﹤0.01%	1671
2022 Q3	$536K	Sell	10,340 -619	-6%	-$36.2K	﹤0.01%	1589
2022 Q2	$518K	Hold	10,959	–	–	﹤0.01%	1639
2022 Q1	$780K	Buy	10,959 +4,139	+61%	+$269K	0.01%	1485
2021 Q4	$510K	Hold	6,820	–	–	﹤0.01%	1500
2021 Q3	$387K	Sell	6,820 -1,474	-18%	-$72.9K	﹤0.01%	1671
2021 Q2	$365K	Hold	8,294	–	–	﹤0.01%	1764
2021 Q1	$409K	Hold	8,294	–	–	﹤0.01%	1644
2020 Q4	$349K	Hold	8,294	–	–	﹤0.01%	1674
2020 Q3	$380K	Hold	8,294	–	–	﹤0.01%	1514
2020 Q2	$416K	Hold	8,294	–	–	﹤0.01%	1485
2020 Q1	$427K	Buy	8,294 +696	+9%	+$37.1K	0.01%	1298
2019 Q4	$469K	Hold	7,598	–	–	﹤0.01%	1500
2019 Q3	$456K	Hold	7,598	–	–	0.01%	1466
2019 Q2	$641K	Hold	7,598	–	–	0.01%	1340
2019 Q1	$726K	Hold	7,598	–	–	0.01%	1227
2018 Q4	$538K	Hold	7,598	–	–	0.01%	1328
2018 Q3	$649K	Hold	7,598	–	–	0.01%	1364
2018 Q2	$881K	Hold	7,598	–	–	0.01%	1076
2018 Q1	$615K	Hold	7,598	–	–	0.01%	1248
2017 Q4	$446K	Buy	+7,598	New	+$380K	0.01%	1464

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MetLife Investment Management's ENTA Position: Q1 2026 in Review

MetLife Investment Management increased its Enanta Pharmaceuticals (ENTA) stake by 7.9% in Q1 2026, buying an estimated $15.2K and bringing the position to 15,542 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #2240.

MetLife Investment Management first reported a position in ENTA in Q4 2017 and has held it in 33 quarters since. The position peaked at $881K in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

MetLife Investment Management held 15,542 shares of Enanta Pharmaceuticals worth $196K as of Q1 2026.
MetLife Investment Management bought 1,134 Enanta Pharmaceuticals shares in Q1 2026, an estimated $15.2K.
Enanta Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2240 holding.
MetLife Investment Management first reported a position in Enanta Pharmaceuticals in Q4 2017 and has held it in 33 quarters since.
MetLife Investment Management's Enanta Pharmaceuticals position peaked at $881K in Q2 2018.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.